HHS just took a step toward the exact future that we’ve built for – bringing peptides out of the gray market, with clinician oversight and quality starting at the source. We’ve taken it one step further by building a US-based supply chain and infrastructure that our customers can trust. This is encouraging progress. More to come.

Today, I’m so proud to share that we're a strategic investor in Arboretum LifeSciences, a next-generation molecular information company. They’re combining genetic testing and AI to scale precision medicine to more conditions and more people. Since meeting the Arboretum team, I have been looking for ways to be a part of getting their innovation into more hands for one simple reason. Giving people the tools to understand their risk before symptoms develop is how you transform a sickcare system into a healthcare system. Understanding your own risk should be a normal part of care, not the exception. It’s the future of health that I believe in and it’s what Hims & Hers is all about. Health that gets smarter over time, adapts with you, and puts actionable information in your hands. This goes beyond rare diseases and can fundamentally change how common conditions like heart disease, diabetes, and neurodegeneration are managed. Today, Arboretum is working with health systems and their providers, and I’m excited for the day that this kind of innovation extends beyond the traditional system (more to come here from us). Congrats to Anthony, Clare, and the entire Arboretum team!